Jefferies Defends Epizyme (EPZM)
Tweet
Share
E-mailGet Alerts EPZM Hot Sheet
Price: $1.47 --0%
Rating Summary:
8 Buy, 5 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 9 | Down: 11 | New: 2
Rating Summary:
8 Buy, 5 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 9 | Down: 11 | New: 2
Join SI Premium – FREE
Jefferies analyst Michael Yee defends Epizyme (NASDAQ: EPZM) following weakness after the FDA briefing documents.
- 'Briefing Documents Read Mixed But We Would Buy on Weakness'
The firm reiterated a Buy rating and $21.00 price target on EPZM.
For an analyst ratings summary and ratings history on Epizyme click here. For more ratings news on Epizyme click here.
Shares of Epizyme closed at $17.71 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Jefferies Downgrades Clorox (CLX) to Hold
- Capricor Therapeutics (CAPR) Falls 26% Following FDA Briefing Docs Post
- FDA approves Freenome's blood-based colorectal cancer screening test
Create E-mail Alert Related Categories
Analyst Comments, FDA, Trader TalkRelated Entities
Jefferies & Co, FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
